BIOMAT Database Logo BIOMAT Database Logo

FDA relaxes cardiovascular trial requirements for diabetes drugs. 2020

Asher Mullard

UI MeSH Term Description Entries

Related Publications

Asher Mullard
FDA cGMP requirements for PET drugs.
May 2011, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Asher Mullard
The new FDA pregnancy labeling requirements for drugs.
January 2011, Journal of midwifery & women's health,
Asher Mullard
FDA moves closer to new requirements for NTI drugs.
September 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Asher Mullard
FDA relaxes proof rules for food health claims.
March 2003, Health news (Waltham, Mass.),
Asher Mullard
FDA considers data confidentiality for diabetes drugs.
October 2014, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Asher Mullard
An analysis of FDA-approved drugs for cardiovascular diseases.
January 2016, Drug discovery today,
Asher Mullard
Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice.
February 2012, Current cardiology reports,
Asher Mullard
FDA ponders cardiovascular risks of ADHD drugs.
March 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Asher Mullard
FDA approach to the regulation of drugs for diabetes.
November 1999, American heart journal,
Asher Mullard
FDA requirements for preclinical studies.
January 2009, Frontiers of neurology and neuroscience,
Copied contents to your clipboard!